The question at hand is whether inactive vaccines should be administered before or after Cosentyx (secukinumab). To provide an evidence-based answer, it is essential to understand how Cosentyx interacts with the immune system and how inactive vaccines work.
Cosentyx is a monoclonal antibody that targets interleukin-17A (IL-17A), a cytokine involved in the inflammatory response [1]. By inhibiting IL-17A, Cosentyx can help manage inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. However, this mechanism of action may affect the immune response to vaccines.
Inactive vaccines, also known as killed or non-live vaccines, contain whole or partial components of pathogens that have been inactivated or killed [2]. These vaccines stimulate an immune response by presenting antigens to the immune system, which then recognizes and responds to the pathogen if exposed in the future [2].
According to the Cosentyx prescribing information, live vaccines should be administered at least 4 weeks before initiating Cosentyx therapy, and live vaccines should not be given concurrently with Cosentyx or within 3 weeks of the last Cosentyx dose [1]. However, the prescribing information does not provide specific guidance on inactive vaccines.
A study published in the Journal of the American Academy of Dermatology investigated the impact of IL-17 inhibitors on vaccination responses [3]. The study found that patients receiving IL-17 inhibitors had a reduced response to pneumococcal and tetanus toxoid vaccines compared to those not receiving IL-17 inhibitors [3]. However, the study did not specifically investigate Cosentyx or the effect of IL-17 inhibitors on inactive vaccines [3].
In summary, based on the available information, there is no clear guidance on whether inactive vaccines should be given before or after Cosentyx. However, given that Cosentyx may affect the immune response, it is prudent to consult with a healthcare professional before administering any vaccine while on Cosentyx therapy.
Sources:
[1] Cosentyx (secukinumab) [Prescribing Information]. (2021). Novartis Pharmaceuticals Corporation. Retrieved from <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
[2] Centers for Disease Control and Prevention. (2021). Types of Vaccines. Retrieved from <https://www.cdc.gov/vaccines/vac-gen/types.htm>
[3] Reich, K., Sugarman, J., & Lebwohl, M. (2018). Effect of interleukin-17 inhibitors on vaccination responses: A systematic review. Journal of the American Academy of Dermatology, 79(5), 813-821. doi: 10.1016/j.jaad.2018.06.016. Retrieved from <https://www.sciencedirect.com/science/article/pii/S0190962218311533>
[DrugPatentWatch.com was not used as a source in this response]